Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
9
×
life sciences
9
×
national blog main
biotech
national top stories
san francisco blog main
san francisco top stories
national
new york blog main
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
raleigh-durham blog main
raleigh-durham top stories
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
crispr therapeutics
investing
merck
pfizer
president trump
roche
sanofi
abbvie
albert bourla
bristol-myers squibb
What
today
9
×
cancer
crispr
drug
future
annual
big
bio
biotech
cas
clinical
medical
medicines
new
oncology
potential
roundup
society
accelerating
acquisitions
ahead
aiming
albert
ambien
ambys
american
asco
attend
attendees
attention
available
away
based
biggest
biopharma's
biopharma’s
biosciences
bird
boston
bourla
Language
unset
unknown
Current search:
today
×
" life sciences "
×
" boston top stories "
×
@xconomy.com
4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Schrödinger Sets Course for IPO to Support Growing Internal Pipeline
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com
5 years ago
ESMO ’18: Precision Meds, Breast, Lung, and More from the Cancer Front
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More